Absci ABSI
NASDAQ ABSI
$8.82 +0.02 (+0.23%)
As of: Sep 4, 2026 · 3:59 PM EDT

Absci (ABSI) Cash from Financing Activities (2020 - 2026)

Absci (ABSI) posted Cash from Financing Activities of $7.6 million for Q1 2026, up 96.67% sequentially from $3.8 million in Q4 2025, and down 82.34% YoY from $42.8 million in Q1 2025.

Analysis

Absci (ABSI) Cash from Financing Activities (2020 - 2026) Analysis & Trends

Absci has reported Cash from Financing Activities for 7 years, with the latest figure at $7.6 million in Q1 2026.

  • Quarterly Cash from Financing Activities fell 82.34% year-over-year to $7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $70.7 million (up 60.21% YoY) and the FY2025 annual result came in at $105.9 million, up 28.38% from the prior year.
  • Cash from Financing Activities improved to $7.6 million in Q1 2026 per ABSI's latest filing, from $3.8 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $81.2 million in Q1 2024 and troughed at -$1.2 million in Q4 2023.
  • A 5-year average of $11.6 million and a median of $490000.0 in 2024 frame the typical range for Cash from Financing Activities.
  • The widest YoY moves for Cash from Financing Activities: up 12209.59% in 2025, down 649.25% in 2025.
  • Over 5 years, Cash from Financing Activities stood at $1.4 million in 2022, then slumped by 188.66% to -$1.2 million in 2023, then soared by 179.84% to $986000.0 in 2024, then soared by 289.66% to $3.8 million in 2025, then jumped by 96.67% to $7.6 million in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods registered $7.6 million, $3.8 million, and $60.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 14.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 2.42 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -6.05 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 36.24 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -273.15 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 27.18 Mn
10 Absci 1.39 Bn 1.19 Bn - 102.73 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 102.73 Mn
Mar 31, 2026 7.56 Mn
Dec 31, 2025 3.84 Mn
Sep 30, 2025 60.32 Mn
Jun 30, 2025 -1.00 Mn
Mar 31, 2025 42.79 Mn
Dec 31, 2024 986,000.00
Sep 30, 2024 490,000.00
Jun 30, 2024 -134,000.00
Mar 31, 2024 81.18 Mn
Dec 31, 2023 -1.24 Mn
Sep 30, 2023 -924,000.00
Jun 30, 2023 -1.22 Mn
Mar 31, 2023 -1.10 Mn
Dec 31, 2022 1.39 Mn
Sep 30, 2022 -921,000.00
Jun 30, 2022 5.82 Mn
Mar 31, 2022 -1.06 Mn
Dec 31, 2021 -1.30 Mn
Sep 30, 2021 208.39 Mn